

July 10, 2025

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
BSE Scrip Code: 524743

To

National Stock Exchange of India Ltd.
Exchange Plaza, 5th floor Plot No. C/ 1, G
Block, Bandra-Kurla Complex Bandra (E),
Mumbai - 400 051
NSE Scrip Code: FISCHER

Dear Sir,

Reg : Fischer Medical Ventures Ltd's public-private partnership with the City of Jember, Indonesia, to support tuberculosis eradication through AI-powered portable X-ray systems

We enclose a press release regarding **"Fischer Medical Ventures Ltd's public-private partnership with the City of Jember, Indonesia, to support tuberculosis eradication through AI-powered portable X-ray systems,"** for dissemination.

Thanking you,
Yours Truly,
For **FISCHER MEDICAL VENTURES LIMITED**
(Formerly known as Fischer Chemic Limited)



ARAVINDKUMAR V
COMPANY SECRETARY & COMPLIANCE OFFICER



CIN L86900AP1993PLC118162

Corporate Office : Level 8, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006
Registered Office : Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyanadu Mandal, Visakhapatnam, 530032

Fischer Medical Ventures Ltd partners with City of Jember to Power Indonesia's Fight Against Tuberculosis

INDIA, 10 July 2025 - **Fischer Medical Ventures Ltd (FMV)** proudly announced a landmark public-private initiative in partnership with the City of Jember, Indonesia, supporting the city with multiple portable, AI-enabled digital X-ray systems designed for mobility, low-radiation exposure, and rapid diagnostics to help **"Free Tuberculosis (TB) in Jember"** by 2026, and to further FMV's commitment to help Indonesia achieve their national goal to eradicate TB by 2030.

Fischer Medical Ventures Ltd has partnered with the City of Jember, Indonesia, to deploy portable, AI-powered X-ray systems aimed at eradicating tuberculosis by 2026. This initiative marks FMV's strategic healthcare entry into Indonesia, combining innovation, access, and impact to transform public health outcomes. The Company is estimating the program value to be over USD 10 million with an implementation plan over 2 years in multiple phases.

For the Company, this initiative is not just exercising its corporate social responsibility, it is a strategic move into a 280 million population country with huge opportunities from its public health plans, especially to fight TB, an infectious disease that can lead to death if not treated promptly. Indonesia continues to battle one of the highest burdens of TB in the world, alongside India and China. A key challenge remains: limited access to early detection and treatment. For many TB patients in Indonesia, the journey to diagnosis often begins with a long wait, and a long difficult walk from remote villages nestled in mountains or coastal towns cut off by poor infrastructure. For someone coughing for weeks, gasping for breath, and unsure whether it's TB or something else, getting to a hospital miles away is a battle they often lose.

Championed by Regent Muhammad Fawait of Jember, this public-private partnership with FMV aims to put Jember citizen at the centre. FMV will support multiple units of portable AI-driven X-Ray, training programs and a comprehensive "Trace, Test, Track" solution to fast-track progress towards a TB-free Jember by ensuring its citizens gain access to early detection, get timely treatment, and receive sustained care. In a country where TB is the fourth leading cause of death, FMV's comprehensive TB solution is changing lives—one patient, one diagnosis at a time, starting with Jember city and rolling out to partner more cities subsequently to help their citizens.





FMV's handheld X-Ray combines mobility, speed, and AI to make healthcare more accessible. Its low radiation, portability, and AI diagnostics make it ideal for rural and underserved areas. Weighing under 3kg, FMV's handheld X-Ray is a significant upgrade from typical bulky, 250kg X-Ray used in TB screening. With this lightweight device, healthcare teams can now reach previously inaccessible areas, from mountain villages to coastal settlements, allowing more agile and efficient service delivery to act faster, reach further, and detect more cases. What makes it truly revolutionary is not just its size, but its AI-powered diagnostic support. With built-in algorithms trained to detect signs of TB in chest X-Rays, frontline health workers can now instantly flag suspected cases, reducing unnecessary sample collection and cutting down the time to diagnosis and treatment, save lives by speeding up everything!

FMV is estimating the program value to be over USD 10 million with an implementation plan over 2 years in multiple phases. With this program, FMV is positioning itself as a trusted partner in Indonesia's healthcare transformation, opening pathways to future collaborations with government health bodies, elevating its brand in one of the world's largest and fastest-growing healthcare markets and building emotional connection and goodwill with over 280 million citizens.

Indonesia Minister of Health, Budi Gunadi Sadikin, expressed his support for the program: "It's excellent that the Regent of Jember is implementing President Prabowo's Quick Win Program for Tuberculosis Eradication through the locally-led initiative 'JEMBER TB-Free 2026.' I fully support this initiative and hope it will inspire other districts and cities across Indonesia to follow Jember City's lead."

Mr. Ravindran Govindan, Executive Chairman & MD of Fischer Medical Ventures Ltd lead this project: *"When we support healthier communities, we're not only doing what is right—we're building a foundation for long-term prosperity and global trust with Indonesian citizens. For shareholders, it signals strategic entry and brand loyalty in high-potential public sector markets that can lead to long-term procurement relationships by enhancing trust among key stakeholders including government ministries, public hospitals, and global health funders."*

While Indonesia has made encouraging strides in TB detection, reporting, and treatment, with marked improvements since 2020, significant challenges—like drug-resistant TB, under-reporting in private sectors, and incomplete surveillance—should continue to be addressed. As Indonesia marches ahead toward a healthier, more resilient future, FMV remains proud to walk alongside its people—one step, one life, one cure at a time. Supporting Healthcare means we should go where people are, technology like FMV's handheld AI-driven X-ray brings access, speed, and accurate diagnostics to support Indonesia's goal to end TB.

For the thousands of children who miss school, the breadwinners who can't work, and the families left grieving, the support from FMV represents more than resources—it represents hope and reinforces the idea that when corporations stand with countries, change becomes not just possible, but inevitable.



For further information, please contact:

Fischer Medical Ventures Limited

Email: enquiry@fischermv.com

Website: www.fischermv.com

Contact: **9080966548**

Disclaimer:

This investor release is not an offer to sell any securities or a solicitation to buy any securities of Fischer Medical Ventures Limited (formerly known as Fischer Chemic Ltd) (the "company") or its subsidiaries (together with the company, the "group"). Certain statements in this document may be forward looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "or" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intention. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

Forward looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Investor Release, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. **FISCHERMVL** will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward- looking statements to reflect subsequent events or circumstances.
